For the Inventor, By the Inventor

Enter assignee name

Parsippany, NJ, United States of America

The Medicines Company

Calculating rank

USPTO Granted Patents = 26

% Expired Patents = 15.4

CIPO Patents = 9

EPO Patents = 19

Trademarks = 2

Forward Citations = 118

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Rajeshwar Motheram (7 out of 14 patents)

Simona Skerjanec (6 out of 15 patents)

Thomas R Parr, Jr (6 out of 8 patents)

4. Adel Rafai Far (6 out of 13 patents)

5. Jayne Prats (5 out of 12 patents)

6. Dario Lehoux (5 out of 6 patents)

7. Gopal Krishna (4 out of 8 patents)

8. Min Ding (4 out of 9 patents)

9. Lisa Ruderman Chen (4 out of 8 patents)

10. Dawn Bell (4 out of 8 patents)

11. Gregory Moeck (4 out of 6 patents)

12. Clive Arthur Arculus-Meanwell (3 out of 8 patents)

13. Evelyne Dietrich (3 out of 12 patents)

14. Meredith Todd (3 out of 7 patents)

15. Mark Harvey Wilcox (3 out of 3 patents)

Core Competencies:

Oritavancin

Cangrelor

Bivalirudin

Ischemic Events

Antimicrobial

Glycopeptide

Lipoglycopeptide

Platelet Inhibition

Pharmaceutical Formulations

Antibiotics

Clostridium Difficile

Infection Treatment

26 patents: Sort by Forward Citations

1. 9775878 - Methods for treating bacterial infections using oritavancin and polymyxins (2017-10-03),

2. 9682061 - Methods of treating bacterial infections using oritavancin (2017-06-20),

3. 9649352 - High purity oritavancin and method of producing same (2017-05-16),

4. 9439921 - Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same (2016-09-13),

5. 9427448 - Methods of treating, reducing the incidence of, and/or preventing ischemic events (2016-08-30),

6. 9320754 - Maintenance of platelet inhibition during antiplatelet therapy (2016-04-26),

7. 9295687 - Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same (2016-03-29),

8. 9220749 - [object Object] (2015-12-29),

9. 9089507 - Use of oritavancin for prevention and treatment of anthrax (2015-07-28),

10. 8946144 - Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections (2015-02-03),

11. 8901072 - Glycopeptide and lipoglycopeptide antibiotics with improved solubility (2014-12-02),

12. 8871736 - Maintenance of platelet inhibition during antiplatelet therapy (2014-10-28),

13. 8815535 - Disk diffusion assay for oritavancin (2014-08-26),

14. 8759316 - Maintenance of platelet inhibition during antiplatelet therapy (2014-06-24),

15. 8754125 - Antimicrobial preservation of propofol emulsions (2014-06-17),

Company Overview

The Medicines Company, based in Parsippany, NJ, is a biopharmaceutical firm focused on developing innovative therapies to address critical medical needs. The company specializes in the research and development of novel treatments, particularly in the areas of cardiovascular and infectious diseases. With a commitment to advancing healthcare, The Medicines Company leverages cutting-edge science and technology to create solutions that improve patient outcomes and enhance the quality of care globally.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

26 Patents

#21 in Parsippany, NJ

#502 in New Jersey

#12,875 in US

#24,848 in the World

Parsippany, NJ, United States of America

The Medicines Company

Forward Citations = 118

40 inventors:

Rajeshwar Motheram (7 out of 14 patents)

Simona Skerjanec (6 out of 15 patents)

Thomas R Parr, Jr (6 out of 8 patents)

4. Adel Rafai Far (6 out of 13 patents)

5. Jayne Prats (5 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: The Medicines Company. Retrieved from https://idiyas.com/company/medicines-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…